Inspiremd, INC 8-K filings

InspireMD has granted inducement awards, including restricted stock units, restricted stock, and stock options, to a new employee as part of their compensation package.

InspireMD has submitted a Premarket Approval application to the FDA for its CGuard Prime carotid stent system, based on positive results from the C-GUARDIANS clinical trial.

InspireMD reported positive one-year outcomes from its C-GUARDIANS clinical trial and a 5.4% increase in second-quarter revenue, while also detailing increased operating expenses.

InspireMD has successfully completed the full exercise of its Series H warrants, generating gross proceeds of $17.9 million to advance its stroke prevention technologies.

InspireMD, Inc. has made available an updated investor presentation on June 13, 2024.

InspireMD's 2024 annual meeting saw the re-election of two directors, approval of executive compensation, and ratification of auditors.

InspireMD, Inc. has entered into an agreement with Piper Sandler & Co. to potentially sell up to $17 million of its common stock through an at-the-market offering.

InspireMD's C-GUARDIANS trial demonstrates a low 1.95% primary endpoint event rate for its CGuard carotid stent system at one-year follow-up.

InspireMD announced a 22% year-over-year increase in CGuard revenue for the first quarter of 2024, alongside progress in clinical trials and key appointments.

InspireMD has amended the employment agreements of its CEO and CFO to include enhanced severance and benefits in the event of a change of control.

InspireMD's C-GUARDIANS clinical trial one-year follow-up results abstract has been accepted for presentation at LINC 2024, showing continued promise for their CGuard Prime Carotid Stent System.

InspireMD announced record fourth-quarter revenue for its CGuard EPS product, alongside positive clinical trial updates and strategic partnerships.

InspireMD has successfully obtained CE Mark recertification for its CGuard Embolic Prevention Carotid Stent System under the European Union's new Medical Device Regulation.